ArticleEmerging microbes & infections2018
Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus.
Article in Emerging microbes & infections, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- A systematic review of SARS-CoV-2 vaccine candidates.Signal transduction and targeted therapy · 2020Pooled it
- Efficacy of Immunostimulatory Adjuvants and Nano-Adjuvants in Current SARS-CoV-2 Vaccines: A Comprehensive Review.Health science reports · 2025Article
- Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection.Vaccines · 2023Review
- Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to theExperimental and therapeutic medicine · 2023Review
- Comparing the Immunogenicity and Protective Effects of Three MERS-CoV Inactivation Methods in Mice.Vaccines · 2022Article
- Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies.Journal of microbiology (Seoul, Korea) · 2022Review
- Review
- A Review on SARS-CoV-2-Induced Neuroinflammation, Neurodevelopmental Complications, and Recent Updates on the Vaccine Development.Molecular neurobiology · 2021Review
- Analysis of COVID-19 vaccines: Types, thoughts, and application.Journal of clinical laboratory analysis · 2021Review
- Nanocarrier vaccines for SARS-CoV-2.Advanced drug delivery reviews · 2021Article
- Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019.Advanced nanobiomed research · 2021Article
- SARS-CoV-2 vaccine research and development: Conventional vaccines and biomimetic nanotechnology strategies.Asian journal of pharmaceutical sciences · 2021Review
- The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies.International immunopharmacology · 2021Review
- Coronavirus vaccine development: from SARS and MERS to COVID-19.Journal of biomedical science · 2020Review
- Vaccines for COVID-19.Clinical and experimental immunology · 2020Review
- Article
- Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development.Virus research · 2020Review
- Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses.International immunopharmacology · 2020Review
- An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies.Expert review of vaccines · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The persistent public health threat of infection with Middle East respiratory syndrome coronavirus (MERS-CoV) highlights the need for an effective and safe MERS-CoV vaccine. In this study, we prepared and vaccinated mice with either a Spike (S) protein or inactivated whole MERS-CoV (IV) with a combined adjuvant (alum+CpG) as a vaccine formulation. Similar levels of the anti-S protein IgG response and neutralizing activity were induced by both the S protein and IV vaccines. In addition, immune responses against three other structural proteins, the envelope (E), membrane (M), and nucleocapsid (N) proteins, were also detected in sera of mice that received IV. No antigen-specific T-cell immunity was detected after vaccination based on the interferon-γ ELISpot assay. Mice were transduced with Ad5-hDPP4 after the final immunization and were then challenged with MERS-CoV (1 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.